PDS Biotechnology Overview
PDS Biotechnology (PDSB) has a PEG ratio of -51.72, below the Healthcare sector average of 27.75.
Get informed when a big investor buys or sells
+ Follow-51.72
The PEG ratio measures a stock's valuation relative to its earnings growth rate. A PEG ratio below 1.0 may indicate that the stock is undervalued relative to its growth potential.
The latest PEG ratio for PDSB is -51.72. That is below the Healthcare sector average of 27.75. Investors often review this figure alongside PDS Biotechnology's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, PDSB currently prints -51.72 for PEG ratio, while the sector average sits near 27.75. That is roughly 286.4% below the sector mean. Large gaps often invite a closer look at PDS Biotechnology's growth, margins, and balance sheet.
A PEG ratio of -51.72 for PDS Biotechnology is not 'good' or 'bad' on its own. Compare it with the peer average (27.75) and with PDSB's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting PDSB's PEG ratio (-51.72), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack PDS Biotechnology's PEG ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
